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Introduction: S100A7 (Psoriasin) is an inflammatory protein known to be upregulated in breast cancer. However,
the role of S100A7 in breast cancer has been elusive, since both pro- and anti-proliferative roles have been reported
in different types of breast cancer cells and animal models. To date, the mechanism by which S100A7 differentially
regulates breast cancer cell proliferation is still not clear.
Methods: We used Gene Functional Enrichment Analysis to search for the determining factor of S100A7 differential
regulation. We confirmed the factor and elaborated its regulating mechanism using in vitro cell culture. We further
verified the findings using xenografts of human breast cancer cells in nude mice.
Results: In the present study, we show that S100A7 significantly upregulates the expression of miR-29b in Estrogen Re-
ceptor (ER)-positive breast cancer cells (represented by MCF7), and significantly downregulates miR-29b in ER-negative
cells (represented by MDA-MB-231). The differential regulation of miR-29b by S100A7 in ER-positive and ER-negative
breast cancer is supported by the gene expression analysis of TCGA invasive breast cancer dataset. miR-29b transcription
is inhibited by NF-κB, and NF-κB activation is differentially regulated by S100A7 in ER-positive and ER-negative breast
cancer cells. This further leads to differential regulation of PI3K p85α and CDC42 expression, p53 activation and
p53-associated anti-proliferative pathways. Reversing the S100A7-caused changes of miR-29b expression by transfecting
exogenous miR-29b or miR-29b-Decoy can inhibit the effects of S100A7 on in vitro cell proliferation and tumor growth
in nude mice.
Conclusions: The distinct modulations of the NF-κB – miR-29b – p53 pathway make S100A7 an oncogene in ER-negative
and a cancer-suppressing gene in ER-positive breast cancer cells, with miR-29b being the determining regulatory factor.
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The inflammatory protein S100A7 (Psoriasin) was discov-
ered as a marker of human psoriasis lesion [1,2]. S100A7
is mainly expressed in epithelial cells [2], and can be
induced by pathogens and inflammatory cytokines [3,4]. It
has been noticed that S100A7 is upregulated in breast
cancer cells [5-7]. However, the role of S100A7 in breast
cancer progression has been elusive, since both pro- and
anti-proliferative roles have been reported in different
types of breast cancer cells and animal models [8-11]. It
has been shown that S100A7 promotes cancer growth and* Correspondence: Mohd.Nasser@osumc.edu; Ramesh.Ganju@osumc.edu
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unless otherwise stated.metastasis in basal-like (ER−) breast cancer cells [10,12].
Accordingly, S100A7 upregulation correlates with poor
prognosis for patients with basal subtype breast carcinoma
[9]. Conversely, it inhibits cancer growth and cell migra-
tion in luminal (ER+) breast cancer cells [8]. To date, the
mechanism by which S100A7 differentially regulates ER−
and ER+ breast cancer cell proliferation is unknown.
microRNAs bind to untranslated regions (UTRs) of
mRNAs, which inhibits protein translation and/or degrades
mRNAs [13]. miR-29b is considered to be a tumor suppres-
sor in multiple types of cancers [14,15], including breast
cancer [16,17]. The anti-cancer effect of miR-29b has been
shown to be related to its targeting of the 3′ UTRs of mul-
tiple key cancer regulators, thus suppressing the growth
and metastasis of breast cancer. miR-29b is encoded by twohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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chromosome 1. It has been shown that NF-κB binds to the
promoter of mir-29b-1 and inhibits its transcription [18]. In
addition, NF-κB has been shown to transactivate YY1,
which then binds to the promoter of mir-29b-2 and inhibits
its transcription [19]. Since NF-κB governs numerous
survival genes and apoptotic genes, its functions in cancer
development has long been noted. The activity of NF-κB
can be either upregulated or downregulated in cancer cells,
depending on whether it is inducing survival signaling or
apoptotic signaling [20]. The differential activation statuses
of NF-κB in different breast cancer subtypes has led to the
discovery of reciprocal regulation of NF-κB by ER [21].
Among the targets of miR-29b, PI3K p85α and CDC42
have been shown to regulate p53 activation [22]. Activated
p53 translocates into the nucleus and activates multiple
anti-proliferative pathways, including the ones of DNA
repair and mitosis check point [23]. It was shown that
miR-29b targets p85α and CDC42 and consequently
inhibits p53 activation and cell proliferation [22].
In the present study, we described a novel role of the
NF-κB – miR-29b – p53 pathway, which defines the
distinct effects of S100A7 on regulating cell proliferation
and tumor growth of ER− and ER+ breast cancer.
Results
S100A7 differentially regulates proliferation of ER− and ER+
breast cancer cells
To investigate the effect of S100A7 upregulation in human
breast cancer, we generated a panel of S100A7 overexpress-
ing breast cancer cell lines [8,10]. S100A7 overexpression
significantly increased the proliferation of ER− MDA-MB-
231 cells and decreased that of ER+ MCF7 cells (Table 1).
Furthermore, with S100A7 overexpression, MDA-MB-231
cells gained mesenchymal properties (fibroblast-like cell
shape and absence of cell-cell adhesion) and increased
tumor growth in nude mice; in contrast, with S100A7 over-
expression, MCF7 cells gained epithelial properties (flat
scale-like cell shape and increased cell-cell adhesion) and
showed reduced tumor growth in nude mice (Table 1).
These observations are in accordance with previous publi-
cations from our group and others [8,10,12]. In this study,




Proliferation change with S100A7 overexpression
Morphology change with S100A7 overexpression
Tumor growth with S100A7 overexpression
Changes of cell proliferation, morphology, tumor formation in nude mice caused by
of cell morphology include fibroblast-like cell shape, absence of cell-cell adhesion; e
adhesion and clustering. (*p < 0.05).cellular models of ER− and ER+ breast cancers to analyze
the mechanism by which S100A7 may differentially regu-
late cell proliferation.
S100A7 overexpression induced differential miR-29b
expression changes in MDA-MB-231 and MCF7 cells
In order to analyze the mechanism by which S100A7
differentially regulates cell proliferation, we characterized
the gene expression signatures in the microarray data of
S100A7 overexpressing MDA-MB-231 and MCF7 cells
(231-S100A7 and MCF7-S100A7). We postulated that we
would pinpoint the driving factor of proliferative regula-
tion by comparing the differential imprints of S100A7
overexpression in the transcriptomes of MDA-MB-231
and MCF7 cells. To do this, we performed the Gene Func-
tional Enrichment (GFE) analysis to the microarray data
of 231-V/231-S100A7 and MCF7-V/MCF7-S100A7 cells
with the bioinformatic engine, ToppGene. We used the
genes which were up-/down-regulated greater than 2 folds
in 231-S100A7 (v.s. vector control) and a comparable
number of genes which were up-/down-regulated greater
than 2.5 folds in MCF7-S100A7 (v.s. vector control) as
training sets for randomized separate GFE analysis. We
then compared the GFE analysis outcomes of these four
sets and discovered a common imprint between MDA-
MB-231 and MCF7 that is associated with opposite
changes of genes: the expression changes of miR-29b
targets. As shown in Figure 1A, miR-29b target genes were
significantly enriched in the genes upregulated in 231-
S100A7 and also in those downregulated in MCF7-
S100A7 cells. miR-29b has been considered a strong
tumor suppressor in multiple cancers. Based on the fact
that miR-29b target genes were upregulated in 231-
S100A7 and downregulated in MCF7-S100A7 cells, we
hypothesized that S100A7 differentially regulates miR-29b
expression which subsequently affects cell proliferation in
MDA-MB-231 and MCF7 cells through modulation of
miR-29b target genes. In order to verify this, we first
analyzed the expression levels of both mature miR-29b
and its two primary microRNAs on chromosome 7 and 1.
In agreement with our GFE analysis, we observed that
S100A7 overexpression significantly downregulated miR-
29b expression in MDA-MB-231 cells and upregulatedan breast cancer cell lines
MDA-MB-231 MCF7
Basal-like Luminal
ER negative ER positive
↑ 57%* ↓ 33%*
Gained mesenchymal Gained epithelial
↑ 1089%* ↓ 79%*
S100A7 overexpression in given cell lines are listed. Mesenchymal properties
pithelial properties include flat and scale-like cell shape, increased cell-cell
** *
**




















































































































Figure 1 (See legend on next page.)
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Figure 1 S100A7 differentially regulates miR-29b transcription and NF-κB activation in MDA-MB-231 and MCF7 cells. (A) GFE analysis was
performed on the top up/down-regulated genes of 231-S100A7 and MCF7-S100A7 cells. Genes up/down-regulated > 2 folds in 231-S100A7 and those
up/down-regulated > 2.5 folds (similar amounts of genes) in MCF7-S100A7 were filtered from microarray data and used as training sets for separate
analysis. Training sets from microarray data are indicated by heat maps, and percentage of miR-29b targets are indicated with pie charts with significance
of enrichment analysis. (B)mature miR-29b was measured by qRT-PCR in the given cell lines, with RNU6B as internal control. Values are not comparable
between MDA-MB-231 and MCF7 cells. (C) primary mir-29b-1 and mir-29b-2 transcript levels were detected by qRT-PCR using specific primers. 18S rRNA
was used as internal control. (D) total cell lysates were subjected to κB-site-DNA-bait ELISA assay to detect total active NF-κB dimer level. Values are not
comparable between MDA-MB-231 and MCF7 cells. (E) cells transfected with NF-κB reporter plasmids were harvested after 48 h, luciferase activity was
analyzed in cell lysates. (F) activated p-p65 subunit of NF-κB in different cells were observed with confocal microscopy. Nuclei were stained with DAPI.
(G) nuclear and cytoplasmic portions of cells were extracted and activated p65 NF-κB were detected with κB-site-DNA-bait ELISA. Data show the relative
percentage of active NF-κB in the two portions. (*p < 0.05, **p < 0.01).
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and primary (pri-mir-29b-1 and pri-mir-29b-2) forms
(Figure 1B, C). Importantly, in agreement with our in vitro
cell line data (Figure 1B, C), analysis of TCGA invasive
breast cancer patient data [24] showed that S100A7 over-
expression in ER+ patients is more likely to correlate with
miR-29b upregulation than ER− patients; and S100A7 over-
expression in ER− patients is more likely to correlate with
miR-29b downregulation than ER+ patients (Additional
file 1: Figures S1, S2 and S3). These data showed that
S100A7 differentially regulates miR-29b transcription in
ER− and ER+ breast cancers.
S100A7 differentially modulates NF-κB activation in MDA-
MB-231 and MCF7
Interestingly, we observed differential regulation of NF-κB
activity by S100A7, which is similar to the differential
regulation of miR-29b expression in MDA-MB-231 and
MCF7 cells. Using both κB-site-DNA-bait ELISA and NF-
κB-luciferase reporter assay, we observed an increase of
NF-κB activity in MDA-MB-231 and a decrease of NF-κB
activity in MCF7 after S100A7 overexpression (Figure 1D,
E). κB-site-DNA-bait ELISA detected the overall activated
p65 NF-κB level, and NF-κB-luciferase reporter assay de-
tected the actual transcription driving NF-κB level. Similar
to changes in NF-κB activation level, we also observed
increased NF-κB nuclear translocation in MDA-MB-231
and decreased NF-κB nuclear translocation in MCF7 after
S100A7 overexpression (Figure 1F, G).
miR-29b transcription is differentially regulated by
S100A7 via NF-κB in MDA-MB-231 and MCF7
miR-29b expression has been shown to be inhibited by NF-
κB in non-breast cancer cells [18,19,25]. We intended to
find out whether S100A7 affected miR-29b transcription
via regulating NF-κB activation in MDA-MB-231 and
MCF7. We first verified that, in breast cancer cells, inhibit-
ing NF-κB activation with its inhibitor, QNZ, significantly
enhanced the transcription of pri-mir-29b-1 and pri-mir-
29b-2 (Figure 2A). This showed that NF-κB activity was
inversely correlated with miR-29b transcription in breast
cancer cells. pri-mir-29b-1 promoter contains three NF-κBbinding sites. The binding of NF-κB to the promoter
directly suppresses pri-mir-29b-1 transcription (Figure 2B).
In addition, NF-κB transactivates the transcriptional factor,
YY1, which in turn can bind to the promoter of pri-mir-
29b-2 to suppress its transcription (Figure 2C). By ChIP
assay and qRT-PCR, we observed that S100A7 overex-
pression differentially altered the binding of NF-κB to the
promoter of pri-mir-29b-1 and/or the expression of pri-
mir-29b-2 suppressor, YY1, in MDA-MB-231 and MCF7
cells (Figure 2D-F). Both direct and indirect transcriptional
regulations by NF-κB led to the differential regulation of
miR-29b levels by S100A7, in MDA-MB-231 and MCF7
cells.
S100A7 downregulates PI3K p85α and CDC42 via
targeting of miR-29b to activate and stabilize p53 in
MCF7
It has been reported that miR-29b activates p53 through
targeting the 3′ UTR of the oncogenes, PI3K p85α and
CDC42 [22] (Figure 3A). Activated (phosphorylated) p53
translocates into nucleus and is protected from degradation
in the cytoplasm (stabilized). We showed that S100A7 in-
duced upregulation of miR-29b in MCF7 cells was able to
reduce the level of p85α and CDC42 proteins (Figure 3B).
Transient knockdown of miR-29b with miR-29b inhibitor
(antagomir) partially rescued the expression of p85α and
CDC42 (Figure 3C, D). Prolonged knock down of miR-29b
by miR-29b-Decoy transfection reduced p53 activation in
MCF7-S100A7 (Figure 3E). Compared to MDA-MB-231,
S100A7 caused a much more dramatic change of miR-29b
in MCF7 cells (Figure 1B). This dramatic rise of miR-29b
led to a significant increase of p53 phosphorylation, nuclear
translocation (Figure 3E-G, Additional file 1: Figure S4)
and total p53 protein level (Figure 3H) in MCF7-S100A7
cells.
S100A7 enhances p53 related anti-proliferative pathways
in MCF7
We further investigated the mechanism by which S100A7
inhibited MCF7 proliferation. p53 pathway qRT-PCR array
data revealed that S100A7 overexpression in MCF7 cells
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Figure 2 S100A7 differentially regulates miR-29b transcription in MDA-MB-231 and MCF7 cells. (A) MCF7 cells were treated with 5nM QNZ for
24 h before they were harvested for qRT-PCR analysis. A well-known NF-κB driven gene GM-CSF served as the positive control for effect of QNZ inhibition.
(B) κB binding sites at the proximal of mir-29b-1 gene transcriptional start site. Two sets of primers, κB-1 and κB-2, were designed to detect three κB
binding sites in ChIP. (C) indirect inhibition of mir-29b-2 transcription by NF-κB and YY1. (D) ChIP assay of NF-κB p65 subunit binding to mir-29b-1
promoter region in 231-V and 231-S cells. (E) ChIP assay of NF-κB p65 subunit binding to mir-29b-1 promoter region in MCF7-V (M-V) and MCF7-S (M-S).
(F) qRT-PCR quantification of YY1 level in different cells. (*p < 0.05, **p < 0.01, N.S.: non-significant).
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targeted apoptotic factors (such as FAS and TNFRSF10B),
p53 targeted DNA repairing factors (such as PCNA and
PTTG1) and p53 targeted anti-survival factors (such as
PTEN) (Figure 4A). Consequently, DNA repair pathway in
MCF7-S100A7 cells was also activated through p53.
Phosphorylation of ATR, Chk-1 and Chk-2 was enhanced
by S100A7, which was absent when p53 is knocked down
in MCF7 cells [26] (Figure 4B, C). S100A7 induced p53
upregulation appeared to be concurrently related with sig-
nificantly enhanced anti-proliferative pathways in MCF7
cells.
S100A7 induced differential regulation of miR-29b is
important for its differential effects on cell proliferation
of MDA-MB-231 and MCF7 in vitro and their tumor
growth in vivo
To verify the importance of miR-29b in determining the
differential effects of S100A7, we stably transfected 231-
S100A7 and MCF7-S100A7 cells with exogenous miR-29b
and miR-29b-Decoy, respectively, to reverse the changes of
miR-29b caused by S100A7 (Figure 5A, C). The S100A7
induced proliferation increase in MDA-MB-231 was re-
pressed by exogenous miR-29b (Figure 5B), and the de-
crease of proliferation in MCF7 was also partially rescuedby miR-29b-Decoy (Figure 5D, Additional file 1: Figure S5).
When we orthotopically injected these cells into nude mice
mammary fat pad, miR-29b overexpression repressed
S100A7 induced tumor growth of MDA-MB-231 cells
(Figure 6A-C), whereas miR-29b knockdown rescued
tumor growth from S100A7 suppression in MCF7 cells
(Figure 6D, E). Thus, we confirmed that miR-29b is the
determining factor of the differential effects of S100A7 in
ER− and ER+ breast cancer cells.
Discussion
In the present article, we proposed a novel mechanism
for the differential roles of the inflammatory protein
S100A7 on the proliferation of ER− and ER+ breast can-
cer cells. S100A7 can either promote or suppress breast
cancer cell proliferation through distinct modulation of
the NF-κB – miR-29b – p53 pathway in ER− MDA-MB-
231 and ER+ MCF7 cells, respectively (summarized in
Figure 7).
miR-29b governs numerous genes’ expression by target-
ing their 3′ UTRs, leading to both translational suppres-
sion and instability of mRNAs. Since large portions of
these regulated genes are associated with cell proliferation,
miR-29b has been considered as a tumor suppressor in

















Figure 3 (See legend on next page.)
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Figure 3 miR-29b targets p85α and CDC42, and determines the effects of S100A7 on p53 activation and stability in different cells. (A)
target sites of miR-29b on 3′ UTRs of CDC42 and p85α mRNAs. (B) WB of p53, p85α and CDC42. β-actin is loading control. (C) miR-29b knockdown by
antagomir inhibitor in MCF7-S cells. (D) WB of transient miR-29b inhibitor transfection partially rescuing p85α and CDC42 protein expression in MCF7-S
cells. (E) prolonged knock down of miR-29b with miR-29b-Decoy reduced p53 phosphorylation and total p53 level in MCF7-S cells. (F) Confocal
microscopy of phosphorylated p53 localization in MCF7-V and MCF7-S cells. Nuclei were labelled with DAPI. (G) relative p53 levels in nuclear extract of
cells. p53 levels were normalized to nuclear marker Oct1. (H) total p53 levels of cells indicating the stability of p53. (*p < 0.05, **p < 0.01).
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tion, miR-29b has also been shown to inhibit breast cancer
metastasis [16]. Through bioinformatic analysis and in vitro
assays, we found that miR-29b expression was reduced by
S100A7 in ER− MDA-MB-231 and increased by S100A7 in
ER+ MCF7 cells, which at least partly explained the differ-
ent roles of S100A7 in regulating proliferation of different
types of breast cancer cells. The clinical relevance of this
was supported by patient data of the TCGA cohort, which
showed that S100A7 upregulation is more likely to be asso-
ciated with increased miR-29b expression in ER+ breast
cancer patients than ER− patients and vice versa. Interest-
ingly, we noticed that, although S100A7 is overexpressed inA
B C
Figure 4 S100A7 activated p53 related anti-proliferative pathways. (A
S100A7 overexpression. (B) WB of p53 and S100A7 in MCF7-p53-CKD trans
knockdown in MCF7-p53-CKD was induced by Doxycyclin (Dox). (C) S100A7 aboth ER− and ER+ breast cancer patients, there is a signifi-
cant mutual-exclusivity of S100A7 and ER expression in
human breast tumors (Additional file 1: Figures S1–S2).
In other words, S100A7 overexpression is more com-
monly seen in ER− tumors. This is in agreement with
previous works based on different cohorts of breast cancer
patients [5].
Moreover, the differential regulation of miR-29b expres-
sion was associated with differential regulation of NF-κB
activation by S100A7. NF-κB has been shown to either
directly or indirectly inhibit the expression of miR-29b,
which is transcribed from mir-29b-1 on chromosome 7
and mir-29b-2 on chromosome 1 [18,19]. Directly, NF-κB) Log2 fold change of mRNA expression of p53 pathway factors after
fected with S100A7 or vector control. p53 shRNA transcription and p53










Figure 5 Manipulating miR-29b could counteract the effects of S100A7 on cell proliferation in MDA-MB-231 and MCF7. The proliferation of
MDA-MB-231 and MCF7 cell lines were determined by MTT assay. (A, C) miR-29b levels of indicated cell lines. (B, D) MTT cell proliferation assays of
indicated cell lines. (*p < 0.05, **p < 0.01).
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scription. Indirectly, NF-κB can transactivate YY1 which
then block the transcription of mir-29b-2 by binding to its
promoter [19]. In the present study, we showed that
S100A7 enhanced NF-κB activity in MDA-MB-231 and
inhibited NF-κB activity in MCF7, which then directly
and/or indirectly influences miR-29b transcription. It was
known that ER negatively regulates activity in breast can-
cer [21,28-30], and may even block the transcriptional
function of NF-κB [30]. Thus, the absence/presence of ER
in breast cancer cells may lead to the differential regula-
tions of NF-κB activation by S100A7 in MDA-MB-231
(ER−) and MCF7 (ER+) cells. In this work, ER status was
used as the primary standard for dividing breast cancer
cells into two groups with distinct responses to S100A7.
To our knowledge, the distinct regulation of NF- κB -
miR-29b by S100A7 is shown for the first time.
Among the targets of miR-29b, PI3K p85α and CDC42
have been shown to be closely related to cancer growth
[22,31,32]. And, as oncogenes, they inhibit the activation
of tumor suppressor, p53 [22]. Activated p53 translo-
cates into the nucleus and avoids degradation in the
cytoplasm. Using MCF7, whose miR-29b was more sig-
nificantly affected by S100A7, we showed that miR-29btargeted PI3K p85α and CDC42, which consequently in-
creased p53 level by enhancing its activation and nuclear
translocation.
Activated p53 can enhance multiple anti-proliferative
pathways to inhibit cancer growth [23]. Here, we showed
that increased p53 activation and total protein level in-
creased the expression of multiple p53 downstream anti-
proliferative factors, including mitosis checkpoint pathways
and DNA repair pathways. These effects were considered
to exert anti-proliferative influences to breast cancer cells.
In addition, we reversed the effects of S100A7 on cell
proliferation and tumor growth by overexpressing miR-
29b in 231-S100A7 cells and knocking down miR-29b in
MCF7-S100A7 cells, which reflected that miR-29b is not
only sufficient but also necessary for determining the
differential effects of S100A7 in breast cancer cells. This
demonstrated that miR-29b functions downstream of
S100A7 and is important in determining the differential
effects of S100A7 in breast cancer cells.
In conclusion, we report a novel regulatory route that de-
termines the pro-/anti-proliferative roles of S100A7 in ER−
and ER+ breast cancer. In these different types of breast
cancer cells, S100A7 differentially regulates NF-κB activa-










M-V M-S M-S-miR-29b-DecoyD E
Figure 6 miR-29b determines the effects of S100A7 on tumor growth of MDA-MB-231 and MCF7 cells. (A and D) representing tumors of
each group at the end of study. Brackets mark the size of tumors on mice. All tumors are to the same scale. (B and E) tumor weight of each
group. *p < 0.05 as analyzed by ANOVA. 231-V and 231-S-miR-29b are not significantly different, neither are MCF7-V and MCF7-S-miR-29b-Decoy.
(C) tumor volume of each group. *p < 0.05 as analyzed by ANOVA. 231-V and 231-S-miR-29b are not significantly different.
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suppress the effects of S100A7 in these cells. Thus, it is sug-
gested that miR-29b may be paired with S100A7 to serve as
more accurate biomarkers for breast cancer diagnosis and
prognosis. On the other hand, S100A7 does not have kinase
activity, which makes it difficult to be targeted with drugs.Recently, many lipid-nanoparticle-based technologies have
made it possible to target miRNAs in clinical trials of can-
cer treatment [33]. Hence, with the discovery of S100A7 -
miR-29b regulatory route, miR-29b may be potential to
serve as an alternative target for S100A7 overexpression in
breast cancer treatment.
Figure 7 Proposed mechanism of differential regulations of NF-κB – miR-29b – p53 pathway by S100A7 in different types of breast cancer cells.
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Reagents and cells
NF-κB p65, p53, PI3K p85α, CDC42, Oct1, β-actin and
GAPDH antibodies and NF-κB inhibitor QNZ were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
miR-29b real-time PCR assay kit and miR-29b inhibitor
were purchased from Life Technologies (Carlsbad, CA). Lu-
ciferase substrate was purchased from Promega (Madison,
WI). p-p53 (S15), p-ATR, p-Chk-1, p-Chk-2 antibodies
were purchased from Cell Signaling Techology (Danvers,
MA). S100A7 antibody was purchased from Novus Biologi-
cals (Littleton, CO). MDA-MB-231 cell and its derivatives
were cultured in DMEM medium supplemented with 10%
FBS and 1% dual antibiotics. MCF7 cell and their deri-
vatives were cultured in MEMα medium supplemented
with 10% FBS and 1% dual antibiotics. p53-conditional-
knockdown-MCF7 cell line was provided by Dr. Jill
Bargonetti (The City University of New York). 231-S-miR-
29b cell was generated by stably transfecting pcDNA3-
miR29b plasmid shared by Dr. Joshua Mendell (Johns
Hopkins University) [34]. MCF7-S-miR-29b-Decoy cell
was generated by stably transfecting AB.pCCL.sin.cPP-
T.U6.miR-29b-Decoy.hPGK.GFP.WPRE plasmid shared
by Dr. Brian Brown (Mount Sinai School of Medicine)
[35].Animal study
Adult female nude mice (NU/NU), obtained from Charles
River Laboratories (Wilmington, MA), were housed under
specific pathogen-free conditions. MDA-MB-231, MCF7 or
their derivatives (3×106 cells/200 μL PBS) were injected into
the right mammary fat pad of each mouse. Mice with MCF7
cell or derivatives were also injected subcutaneously with
2.5 μg of β-estradiol 17-valerate in 50 μL of Sesame oil once
a week. Tumor size was assessed once a week and tumor
volume was calculated using digital calipers according to the
formula: volume = length × (width)2 / 2. Mice were sacrificed
at the end of study or per the request of the veterinarian. Allmice were kept in OSU’s animal facility in compliance with
the guidelines and protocols approved by the IACUC.
Gene functional enrichment analysis
Gene functional enrichment (GFE) analysis is performed
using the bioinformatics engine, ToppGene [36], devel-
oped by the Division of Biomedical Informatics, Cincinnati
Children’s Hospital Medical Center (Cincinnati, OH).
Training gene list was determined by gating the signifi-
cantly up-/down-regulated genes from microarray data
as specified. Enrichment analysis was corrected by
Bonferroni method with a p-Value cutoff of 0.05.
Quantitative reverse transcription–PCR (qRT-PCR)
qRT-PCR was performed as previously described [37].
Briefly, total RNA was extracted from cells using TRIzol
reagent (Life Technologies) and purified with RNeasy kit
(Qiagen, Valencia, CA). For mRNA detection, total RNA
was then reverse transcribed into cDNA using High
Capacity cDNA Reverse Transcription Kit (Life Technolo-
gies) and quantified using Power SYBR Green Master Mix
(Life Technologies). p53 pathway PCR array was performed
using p53 Signaling Pathway RT2 Profiler PCR Array from
Qiagen. For miRNA detection, total RNA was reverse tran-
scribed and miRNAs quantified using miRNA specific real-
time PCR kits from Life Technologies. Real-time PCR was
performed on Eppendorf Mastercycler realplex. Data ana-
lysis was performed using standard “delta delta Ct method”.
NF-κB activity assays
For the κB-site-DNA-bait ELISA assay, nuclear and cyto-
plasmic extractions of cells were prepared using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientific) per the product manual. Activated NF-κB p65
levels of both nuclear and cytoplasmic extracts were mea-
sured using TransAM NF-κB p65 Transcription Factor
ELISA Kit (Active Motif, Carlsbad, CA) per the product
manual. For the luciferase reporter assay, cells were
Zhao et al. Molecular Cancer  (2015) 14:11 Page 11 of 12transfected with equal amount of pNF-κB-Luc reporter
plasmids by lipofectamine 2000 (Life Technologies) and
harvested after 48 h. Cells were lysed and luciferase activ-
ity was measured with the luciferase assay kit from
Promega (Madison, WI) and Synergy plate reader (BioTek,
Winooski, VT) per the manufacturer’s manual.Confocal microscopy
Cells grown on micro-chamber-slides were fixed and per-
meabilized using the Fix/Perm solution (BD Biosciences,
San Jose, CA) for 20 min at 4°C. The cells were washed
with BD Perm/Wash buffer (BD Biosciences), and stained
with respective primary antibodies for 1 h at 4°C. After the
incubation, cells were washed and stained with Alexa
Fluor 488 or 568 secondary antibodies for 1 h at 4°C. The
slides were mounted using Vectashield mounting medium
with DAPI (Vector Laboratories) and then imaged with
Olympus FV1000 confocal microscope. The pictures were
processed using Olympus FV-10 ASW software.Chromatin immunoprecipitation (ChIP)
Cells were fixed and cross-linked in 2% paraformaldehyde,
and then cross-linking was quenched with 10% volume of
1.375 M glycine. After washing with ice cold PBS, cells
were harvested and lysed with NP-40 ChIP buffer. Nuclei
were isolated by centrifuge, and lysed with SDS nuclei lysis
buffer. DNA was digested using Micrococcal Nuclease
from New England Biolabs, and digestion was stopped by
adding 50 mM EDTA. DNA samples were then immuno-
precipitated overnight at 4°C with NF-κB p65 antibody
and Protein G/Protein A Agarose Beads (Calbiochem).
After washing, DNA was eluted using SDS elution buffer,
and then reverse cross-linked by incubation overnight
at 65°C. DNA was purified using TRIzol reagent (Life
Technologies) and chloroform, and then subjected to
PCR with specific primers.Cell proliferation assay
Cell proliferation assay was performed using Cell Prolifer-
ation Kit I (MTT) from Roche (Indianapolis, IN) per the
kit manual. Proliferation assays were done in triplicates.
O.D. values were measured using Model 680 microplate
reader from BIO-RAD (Hercules, CA).Western blotting (WB)
WB was performed as previously described [37]. Briefly,
proteins in cell lysates were separated by electrophoresis
using NuPAGE SDS PAGE Gel (Life Technologies). Pro-
teins transferred onto Nitrocellulose membrane were then
blotted by specific primary and HRP-conjugated secondary
antibodies. Protein expression was detected by Thermo
ECL reagents using X-ray films.Statistical analysis
Reported data for cell line studies are the means ±
S.E.M. of at least three independent experiments per-
formed in duplicates or triplicates. Animal studies use n
= 5 ~ 8 mice for each group. The statistical significance
was determined by the Student’s t test or as specified.
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